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A BS T R AC T
Background
The combination of ataxia and hypogonadism was first described more than a 
century ago, but its genetic basis has remained elusive.
Methods
We performed whole-exome sequencing in a patient with ataxia and hypogonado-
tropic hypogonadism, followed by targeted sequencing of candidate genes in simi-
larly affected patients. Neurologic and reproductive endocrine phenotypes were 
characterized in detail. The effects of sequence variants and the presence of an 
epistatic interaction were tested in a zebrafish model.
Results
Digenic homozygous mutations in RNF216 and OTUD4, which encode a ubiquitin E3 
ligase and a deubiquitinase, respectively, were found in three affected siblings in a 
consanguineous family. Additional screening identified compound heterozygous 
truncating mutations in RNF216 in an unrelated patient and single heterozygous 
deleterious mutations in four other patients. Knockdown of rnf216 or otud4 in zebra-
fish embryos induced defects in the eye, optic tectum, and cerebellum; combinatorial 
suppression of both genes exacerbated these phenotypes, which were rescued by 
nonmutant, but not mutant, human RNF216 or OTUD4 messenger RNA. All patients 
had progressive ataxia and dementia. Neuronal loss was observed in cerebellar 
pathways and the hippocampus; surviving hippocampal neurons contained ubiqui-
tin-immunoreactive intranuclear inclusions. Defects were detected at the hypotha-
lamic and pituitary levels of the reproductive endocrine axis.
Conclusions
The syndrome of hypogonadotropic hypogonadism, ataxia, and dementia can be 
caused by inactivating mutations in RNF216 or by the combination of mutations in 
RNF216 and OTUD4. These findings link disordered ubiquitination to neurodegen-
eration and reproductive dysfunction and highlight the power of whole-exome se-
quencing in combination with functional studies to unveil genetic interactions that 
cause disease. (Funded by the National Institutes of Health and others.)
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In recent years, we have seen great ad-vances in the elucidation of genetic causes of cerebellar ataxia, with newly identified genes 
regulating a wide spectrum of cellular functions, 
including intracellular signaling, tau regulation, 
and mitochondrial function.1 However, a genetic 
defect cannot be found in approximately 40% of 
patients with ataxia,1 including those in whom 
ataxia is associated with reproductive endocrine 
failure, a syndrome first reported by Gordon 
Holmes in 1908.2 Most patients with this syn-
drome have a hypogonadotropic condition, with 
defective secretion of gonadotropins by the pitu-
itary gland.3-12 Strikingly, genes associated with 
ataxia have little functional overlap with genes 
associated with hypogonadotropic hypogonadism, 
which encode proteins involved in the biologic 
function of the neurons that secrete gonadotropin-
releasing hormone (GnRH).13
A decade ago, we described a consanguineous 
family with a syndrome of cerebellar ataxia, de-
mentia, and hypogonadotropic hypogonadism.12 
Here we report the results of whole-exome and 
targeted sequencing performed to identify muta-
tions that underlie the syndrome in this kindred 
and in unrelated patients.
ME THODS
Study Patients
Our study included 12 patients with ataxia and 
hypogonadotropic hypogonadism from eight fam-
ilies. The pedigrees of the index family and four 
of the other seven families are shown in Figure 1. 
The patients were referred to the Massachusetts 
General Hospital for clinical or genetic evalua-
tion between 2000 and 2010. The study was ap-
proved by the hospital’s human research com-
mittee, and written informed consent for all 
participants was provided by the participant or 
an authorized representative.
Genetic Analysis
We performed exome sequencing with DNA from 
Patient 3 in the index family. The data sets used 
for exome analysis in this study were obtained 
from dbGaP at www.ncbi.nlm.nih.gov/gap 
through dbGaP accession number phs000475.
v1.p1. Candidate genes were sequenced in family 
members and in unrelated affected persons. Com-
puter algorithms were used to predict the patho-
genicity of variants and to identify interactions 
between candidate genes and genes known to be 
associated with ataxia or hypogonadotropic hy-
pogonadism. Allele-specific reverse-transcrip-
tase–polymerase-chain-reaction (RT-PCR) assays 
were performed with RNA from Patients 5, 6, 
and 7 (see the Methods section in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org). 
Neuropathological and Endocrine 
Evaluation
The brain of Patient 2 was obtained within 6 hours 
after death. Immunohistochemical analysis was 
performed with the use of antibodies against 
ubiquitin, tau, and α-synuclein. Electron micros-
copy was performed according to standard pro-
cedures. Detailed reproductive endocrine pheno-
typing was performed in 5 patients, as described 
in our previous report12 and in the Methods sec-
tion in the Supplementary Appendix.
Zebrafish Investigations
Morpholino oligonucleotides (MO) for the silenc-
ing of zebrafish rnf216 and otud4 were injected 
either alone or with nonmutant or mutant hu-
man messenger RNA (mRNA) encoding RNF216, 
mRNA encoding OTUD4, or both (see the Meth-
ods section in the Supplementary Appendix).
R ESULT S
Genetic Studies
The consanguineous pedigree of the index family 
(a self-reported Palestinian family) includes three 
siblings (Patients 1, 2, and 3) with ataxia and 
hypogonadotropic hypogonadism. Exome sequenc-
ing performed with DNA from Patient 3 identi-
fied 13 homozygous variants that were rare and 
predicted to be deleterious (Table S1 in the Sup-
plementary Appendix), 2 of which were also ho-
mozygous in the two other affected siblings: 
RNF216 (NM_207111.3) c.2251C→T, p.R751C and 
OTUD4 (NM_001102653.1) c.998G→T, p.G333V; 
these variants were not identified or were hetero-
zygous in the unaffected family members (Fig. 1). 
RNF216 encodes an E3 ubiquitin-protein ligase. 
The R751 residue of RNF216 resides within the 
second of two domains called “really interesting 
new gene” (RING) finger domains and is con-
served across vertebrates (Fig. S1 in the Supple-
mentary Appendix). The R751C variant is pre-
dicted to be deleterious by four prediction 
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programs and is absent in 13,006 control chro-
mosomes from the National Heart, Lung, and 
Blood Institute’s Exome Sequencing Project (ESP) 
and in 672 chromosomes from Middle Eastern 
persons (including 36 chromosomes from Pales-
tinian persons). OTUD4 encodes a deubiquitinase 
B Pedigrees for Patients 4–8
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(Fig. S1 in the Supplementary Appendix). The 
G333V variant is predicted to be deleterious by 
three of four prediction programs and is found in 
2 of the 13,006 chromosomes from the ESP and 
in none of the 672 chromosomes from Middle 
Eastern persons.
Both OTUD4 and RNF216 were sequenced in 
nine affected persons from seven unrelated 
families. No rare variants were identified in 
OTUD4, but mutations in RNF216 were identified 
in four probands (Fig. 1, and Fig. S1 in the 
Supplementary Appendix). Patient 4 had com-
pound heterozygous frameshift and nonsense 
mutations ([c.615_616delGA; p.E205DfsX15] and 
[c.1791T→A; p.C597X]). Three additional hetero-
zygous mutations were identified: c.414delG, 
p.G138GfsX74 in Patients 5 and 6 (siblings); 
c.721C→T, p.Q241X in Patient 7; and c.2149C→T, 
p.R717C in Patient 8; the missense mutation in 
Patient 8 was predicted to be deleterious by four 
prediction programs.
None of these RNF216 variants were present 
in the ESP, which did identify five other variants 
considered to be overtly deleterious and nine con-
sidered likely to be deleterious. Given this back-
ground level of genetic variation, the presence of 
deleterious mutations in five of eight probands in 
this study exceeded what would be expected by 
chance (P<1×10−13 by Fisher’s exact test). Grail,14 
DAPPLE,15 Endeavour,16 InWeb scored network,17 
and CNVconnect18 were used to identify potential 
connections among RNF216, OTUD4, and genes 
known to be associated with ataxia or hypogo-
nadotropic hypogonadism; no such connections 
were found. Allele-specific RT-PCR assays failed 
to identify occult mutations affecting transcrip-
tion or mRNA stability in the nonmutant alleles 
of Patients 5, 6, and 7 (Fig. S2 in the Supplemen-
tary Appendix).
Functional Testing
Zebrafish were used to interrogate the functional 
consequences and suggestive epistatic interac-
tions of the RNF216 and OTUD4 mutations.19,20 
The injection of a MO that disrupted the splicing 
of zebrafish rnf216 (Fig. S3 in the Supplementary 
Appendix) caused a reduction in the size of the 
eye cup and optic tecta and disorganization of 
the cerebellum, as well as a slight reduction in 
overall head size (Fig. 2 and 3, and Fig. S4 in the 
Supplementary Appendix). The tectal phenotype 
was rescued by the coinjection of human RNF216 
mRNA, but the injection of human RNF216 
mRNA encoding R751C failed to rescue the phe-
notype (Fig. 2), suggesting that the mutation af-
fects the function of the encoded protein. The 
injection of a splice-blocking MO against zebra-
fish otud4 (Fig. S3 in the Supplementary Appen-
dix) also induced a reduction in size of the optic 
tecta and cerebellum (Fig. 3).
Coinjection of both rnf216 and otud4 MOs 
induced a significant reduction in the size of the 
optic tecta as compared with the injection of the 
rnf216 MO alone (P<0.001) (Fig. 3). Double-MO 
injection also caused marked disorganization of 
the cerebellum in more than 60% of embryos 
(Fig. 3) and the development of a severe cerebel-
lar phenotype with complete loss of structural 
integrity in approximately 30% of embryos, as 
compared with only 5 to 10% of embryos injected 
with either the rnf216 or the otud4 MO alone 
(data not shown). Furthermore, double-MO in-
jection resulted in marked microphthalmia as 
compared with modest micro phthalmia when 
either MO injection was used alone (Fig. S4 in 
the Supplementary Appendix). These phenotypes 
were specific, since coinjection of nonmutant hu-
man RNF216 or OTUD4 mRNA rescued all phe-
notypes (Fig. 3, and Fig. S4 in the Supplemen-
tary Appendix). RNF216 mRNA encoding R751C 
and OTUD4 mRNA encoding G333V were less 
effective in rescuing the phenotypes induced by 
double-MO injection (Fig. 3, and Fig. S4 in the 
Supplementary Appendix), suggesting not only 
that these mutant alleles encode functionally 
deficient proteins but also that epistatic interac-
Figure 1 (facing page). Segregation of RNF216 and 
OTUD4 Mutations in the Index Pedigree and Identifi-
cation of Additional RNF216 Mutations in Unrelated 
Probands.
The seven-generation pedigree shown in Panel A includes 
Patients 1, 2, and 3, all of whom presented with ataxia, 
dementia, and hypogonadotropic hypogonadism and 
were homozygous for both RNF216 p.R751C and OTUD4 
p.G333V. Double lines indicate consanguineous unions. 
Genotyped, unaffected family members are shown to 
be either homozygous for the nonmutated alleles (de-
noted with a + symbol) or heterozygous for one or both 
changes. The pedigrees shown in Panel B are for the 
families of additional RNF216 mutation-positive patients 
(Patients 4 through 8), all of whom presented with 
ataxia and hypogonadotropic hypogonadism. Squares 
denote male family members, circles female family 
members, solid symbols affected family members, 
slashes deceased family members, diamonds siblings 
of either sex, the triangle miscarriages, and Arabic 
numbers the number of siblings or miscarriages.
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tions between these mutations contribute to the 
disease phenotype in the index pedigree.
Clinical Characteristics of the Study 
Patients
Patients 1 through 8, who carried variants in 
RNF216, had similar clinical histories (Table 1). 
They presented in adolescence or early adulthood 
with hypogonadotropic hypogonadism but no 
other pituitary abnormalities. Dysarthria was the 
initial neurologic symptom in some patients, but 
ataxia developed in all patients, leading to wheel-
chair dependency and to bed confinement for 
some patients. Dementia was also prominent, 
with personality changes and memory loss oc-
curring at the onset of the disease and mutism 
and uncoordinated, purposeless movements dur-
ing the end stages. Nystagmus was absent. The 
presentation of Patients 9 through 12, who did 
not have variants in RNF216, was quite different 
from that of Patients 1 through 8 (Table 1). Ex-
tensive evaluation did not reveal any known 
causes of ataxia in any of the patients; mitochon-
drial abnormalities were identified in Patients 7 
and 8 (Table S2 in the Supplementary Appendix).
Neuroimaging performed in Patients 1 through 
8 revealed striking similarities, with cerebellar 
and cortical atrophy but no abnormalities of the 
pituitary gland. The subcortical white matter 
contained patchy areas of hyperintensity on 
T2-weighted imaging and fluid-attenuated inver-
sion recovery (FLAIR) imaging (Table 1 and Fig. 
4). In Patient 7, these areas of hyperintensity 
were present approximately 9 years before the 
onset of neurologic symptoms; the cerebellum 
appeared normal at that earlier point in time.
Neuropathological Studies
The formalin-fixed brain of Patient 2 weighed 
940 g (normal weight, 1300 g). The cerebellum 
and inferior olives were atrophic. Histopatholog-
ical analysis revealed gliosis and virtually com-
plete loss of inferior olivary neurons, cerebellar 
Purkinje’s cells, and neurons in hippocampal re-
gions CA3 and CA4, whereas neurons were well 
preserved in regions CA1 and CA2. Ubiquitin-
immunoreactive nuclear inclusions were present in 
1 to 5% of the pyramidal neurons in hippocam-
pal regions CA1 and CA2 (Fig. 4) and were also 
found in granule-cell neurons in the dentate gyrus; 
these inclusions were not immunoreactive to an-
tibodies against tau or α-synuclein (not shown). 
R
el
at
iv
e 
O
pt
ic
 T
ec
tu
m
 A
re
a 
(A
U
)
155
145
150
140
135
5
0
Control rnf216 MO MO+Nonmutant
RNF216
MO+Mutant
RNF216
E Size of Optic Tectum
P<0.001
P<0.001 P=0.002
A Control
C MO+Nonmutant RNF216
B rnf216 MO
D MO+Mutant RNF216
Figure 2. Functional Studies of rnf216 in Zebrafish.
Panels A through D show dorsal views of control zebrafish embryos (Panel A) 
and embryos injected with rnf216 morpholino oligonucleotides (MO) (Panel B), 
rnf216 MO plus nonmutant human RNF216 (Panel C), and rnf216 MO plus 
mutant human RNF216 (with RNF216 carrying the p.R751C mutation identified 
in the index pedigree) (Panel D) at 3 days after fertilization (staining with an 
antibody against α acetylated tubulin). The circles outline the area of the 
optic tectum, the structure on which all measurements were based. The bar 
graph in Panel E shows the relative size of the optic tectum in control embryos 
and the embryos injected with rnf216 MO, rnf216 MO plus nonmutant human 
RNF216, and rnf216 MO plus mutant human RNF216. P values are based on 
two-tailed t-tests. I bars indicate standard errors. AU denotes arbitrary units.
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Figure 3. Epistatic Effects of the OTUD4 p.G333V Allele.
Panels A through F show dorsal views of control zebra-
fish embryos (Panel A) and embryos injected with 
rnf216 MO (morpholino oligonucleotides) (Panel B), 
otud4 MO (Panel C), double MO (DMO, rnf216 MO 
plus otud4 MO) (Panel D), double MO plus nonmutant 
human OTUD4 (Panel E), and double (DMO) plus mu-
tant human OTUD4 (OTUD4 carrying the p.G333V 
mutation identified in the index pedigree) (Panel F)  
at 3 days after fertilization (anti-α acetylated tubulin 
stain). The asterisks indicate the optic tecta that were 
measured to assess the differences between the condi-
tions being evaluated. The bar graph in Panel G shows 
the mean relative size of the optic tecta in control em-
bryos and the five groups of injected embryos. I bars 
indicate standard errors. P values are based on two-tailed 
t-tests. Panels H, I, and J show dorsal views of control 
embryos (Panel H) and embryos injected with DMO 
(Panel I) and DMO plus nonmutant human OTUD4 
(Panel J) at 3 days after fertilization (anti-α acetylated 
tubulin stain). The rectangles outline the cerebellar 
area; maximum disorganization is observed in embryos 
injected only with DMO (Panel I). The bar graph in 
Panel K shows the percentage of embryos with cerebellar 
defects under the conditions being evaluated (as shown 
in Panels A through F and Panels H, I, and J).
On electron microscopy, the intranuclear inclu-
sions appeared as aggregates of fine filaments 
and granular material (Fig. 4).
Reproductive Endocrine Studies
When Patient 6 reached 32 years of age, 1 year 
after the development of neurologic symptoms, 
low-amplitude pulses of luteinizing hormone 
were detected, indicating that GnRH secretion, 
although present, was diminished (Fig. 5). The 
administration of pulsatile GnRH for 7 days in-
duced robust increases in levels of gonadotropins 
and estradiol (Fig. 5) as well as the growth of a 
dominant ovarian follicle, observed on ultraso-
nography (not shown). Although the secretion of 
luteinizing hormone increased in response to the 
administration of GnRH, the typical peaked pat-
tern of luteinizing hormone pulses21 was not seen, 
which suggested a degree of pituitary dysfunc-
tion. Indeed, the patient’s pituitary responsiveness 
waned over time, with a diminished response to 
GnRH on day 1 of treatment 15 months after the 
initial endocrine study (Fig. 5).
In Patient 8, in whom endocrine function was 
initially assessed before the onset of neurologic 
symptoms, there was an absence of endogenous 
pulsatile luteinizing hormone secretion (Fig. 5). 
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After escalating doses of exogenous GnRH (from 
25 ng per kilogram of body weight to 600 ng per 
kilogram every 2 hours), the patient’s testicular 
volume increased from 2 ml to 8 ml but did not 
increase further, despite these very high doses. 
Although his pituitary response to exogenous 
treatment with GnRH was impaired (Fig. 5), di-
rect gonadal stimulation with human chorionic 
gonadotropin normalized the testosterone level, 
at 459 ng per deciliter (15.9 nmol per liter).
Pituitary responsiveness to GnRH was lost in 
patients late in the course of their disease. In 
Patients 1 and 2, who were bedridden when pi-
tuitary responsiveness was assessed, there was 
no detectable luteinizing hormone secretion and 
no measurable change in the gonadotropin level 
in response to the administration of pulsatile 
exogenous GnRH (Fig. 5).12
DISCUSSION
The underpinnings for the association of ataxia 
with hypogonadotropic hypogonadism have elud-
ed investigators for more than a century. This 
report shows that ataxia with hypogonadotropic 
hypogonadism can be caused by mutations in 
RNF216 either singly or in combination with mu-
tations in OTUD4. Both RNF216 and OTUD4 en-
code proteins that regulate ubiquitination, indi-
cating that abnormalities in this fundamental 
cellular process can have pathologic effects on the 
cerebellum and hippocampus, the cerebral white 
matter, and the hypothalamic and pituitary com-
ponents of the reproductive endocrine cascade.
The compound heterozygous termination mu-
tations in RNF216 in Patient 4 firmly implicate 
RNF216 as a causative gene for this syndrome. 
Heterozygous RNF216 mutations were found in 
Patients 5 through 8 but did not cause disease in 
their parents. Oligogenicity offers a parsimoni-
ous explanation for these observed patterns. 
Oligogenic inheritance has been described in the 
Bardet–Biedl and Bartter syndromes, Hirsch-
sprung’s disease, and isolated hypogonadotropic 
hypogonadism.19,22-27 In such an oligogenic mod-
el, RNF216 mutations can act with mutations at 
other genetic loci to cause disease.
Indeed, the phenotype in the index pedigree 
appears to have been caused by the interaction of 
hypomorphic mutations in RNF216 and OTUD4. 
Inhibition of either RNF216 or OTUD4 in zebra-
fish resulted in cerebellar hypoplasia, microph-
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thalmia, and small optic tecta. The concordance 
of these phenotypes suggests that RNF216 and 
OTUD4 operate in the same pathway. This possi-
bility is bolstered by the observation of epistatic 
interactions between RNF216 and OTUD4, with si-
multaneous knockdown of both genes resulting in 
more severe phenotypes. Taken together, these 
findings support a digenic model in which the 
OTUD4 mutation, in conjunction with the RNF216
mutation, played an essential role in causing dis-
ease in the index pedigree. By extension, in Pa-
tients 5 through 8, it is possible that mutations 
in other, currently unidentified loci may have 
acted in conjunction with the heterozygous mu-
tations in RNF216 to cause disease. Oligogenicity 
is likely to be increasingly recognized as meth-
ods for detecting this genetic architecture, such 
as exome sequencing, are more widely adopted.
A B
DC
Figure 4. Neuroradiologic and Neuropathological Findings.
Panel A shows a sagittal T2-weighted magnetic resonance imaging scan of the brain in Patient 3. Diffuse cerebellar 
atrophy (arrow) and cortical atrophy can be seen. Panel B shows a transverse image obtained with fluid-attenuated 
inversion recovery imaging, revealing multiple distinct and confluent foci of hyperintensity in the white matter. In 
Panel C, immunohistochemical analysis of a hippocampal brain section from Patient 2 shows a neuronal intranuclear 
inclusion with immunoreactivity (brown) to an antibody against ubiquitin, counterstained with hematoxylin and eosin. 
An electron micrograph of the hippocampal neurons, in Panel D, also shows an intranuclear inclusion, which con-
sists of aggregates of granular material and fine filaments, 10 to 15 nm in diameter (arrow), that are for the most 
part randomly oriented. The scale bar corresponds to 1 μm.
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RNF216 encodes an E3 ubiquitin ligase that 
attaches ubiquitin to protein substrates, mark-
ing them for proteasome-mediated degradation. 
Known targets of RNF216 include upstream 
activators of nuclear factor κB signaling, which 
regulates diverse cellular processes.28-31 RNF216 
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Figure 5. Endocrine Phenotypes.
In Panels A through D, the graphs at the left show the endogenous secretion of luteinizing hormone over a period of up to 12 hours.  
Patient 6 was studied on two occasions, 15 months apart (Panels A and B). Arrowheads indicate pulses of luteinizing hormone secretion, 
and boxes duration of sleep; the shading indicates the reference range for healthy men and women. Concentrations of estradiol (E2) and 
testosterone (T), measured from pooled samples obtained during the study, are indicated. In Panels A, B, and D, the graphs at the right 
show the response to exogenous pulsatile gonadotropin-releasing hormone (GnRH) over the course of up to 7 days. The dose of GnRH 
was 75 ng per kilogram of body weight, with the exception of the first dose of GnRH on day 1 for Patient 6 (Panel A), which was 165 ng 
per kilogram. (Note the difference in the y axis scales in Panels A and B.) In Panel C, the graph at the right shows the secretion of lutein-
izing hormone in response to varying doses of GnRH (black circles and regression line). The data for the patient fall to the right of the 
95% confidence interval (dashed red lines) for the mean amplitude of the response to a range of GnRH doses in 6 other men with idio-
pathic hypogonadotropic hypogonadism (solid red line).
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is structurally similar to parkin, an E3 ubiquitin 
ligase that is mutated in a recessive form of 
Parkinson’s disease.32-34 The finding of neuro-
nal intranuclear inclusions in Patient 2 may 
indicate that RNF216-associated neurodegenera-
tion has similarities not only with Parkinson’s 
disease but also with other neurodegenerative 
disorders in which protein aggregates are found, 
such as Huntington’s disease and Alzheimer’s 
disease.35
OTUD4 encodes a deubiquitinating enzyme. 
Deubiquitinases allow target proteins and ubiq-
uitin itself to be recycled and often function in 
partnership with specific E3 ligases. For exam-
ple, the deubiquitinase ataxin-3 counteracts the 
ability of parkin to ubiquitinate itself.36 On the 
basis of this and other examples,37 OTUD4 and 
RNF216 may be similarly linked in a coregula-
tory partnership.
The progressive and debilitating dementia ob-
served in the patients with RNF216 mutations 
(Patients 1 through 8) distinguishes them from 
the other patients with ataxia and hypogonado-
tropic hypogonadism. Furthermore, we observed 
changes in cerebral white matter in all the pa-
tients with RNF216-associated neurodegenera-
tion, suggesting that such changes may consti-
tute a consistent feature of this syndrome. None 
of these patients had oculomotor abnormalities 
such as the nystagmus and ophthalmoplegia 
seen in Patients 9, 10, and 12, who did not have 
RNF216 mutations.
The patients with RNF216-associated neuro-
degeneration had dysfunction at multiple levels 
of the reproductive endocrine axis. In Patients 6 
and 8, reproductive function was restored with 
extended GnRH treatment, which suggests that 
hypothalamic GnRH deficiency was the primary 
cause of their reproductive endocrine dysfunction. 
However, these two patients also appeared to 
have an element of pituitary dysfunction, given 
the diminishing responses to GnRH over time in 
Patient 6 and the observation of a right-shifted 
dose–response curve in Patient 8. In Patients 1 and 
2, who were evaluated late in the course of their 
disease, the complete absence of response after 
7 days of treatment with GnRH may represent 
progression of this pituitary dysfunction. The 
basis for the selective vulnerability of particular 
neuronal and pituitary cell types is currently 
unexplained.
In conclusion, we have identified loss-of-func-
tion mutations in RNF216 that cause a syndrome 
of ataxia, dementia, and hypogonadotropic hypo-
gonadism. Genetic and in vivo evidence suggests 
that mutations affecting RNF216, an E3 ubiqui-
tin ligase, and OTUD4, a deubiquitinase, can 
synergize to cause this syndrome, reinforcing 
the notion that the mutational load within bio-
logic pathways can drive disease manifesta-
tion.20 Taken together, these data highlight a 
hitherto unknown role of the ubiquitination 
system in disorders of combined neurodegenera-
tion and reproductive dysfunction. More broadly, 
our findings show the value of combining indi-
vidual whole-exome sequencing with in vivo func-
tional studies to identify disease-causing gene 
mutations and epistatic interactions.
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